source
- Takeda's zasocitinib clears scalp psoriasis in 75% of patients in phase 3 dataTakeda released updated results from its two phase 3 trials of the oral TYK2 inhibitor zasocitinib, enrolling a total of 1,801 patients with moderate-to-severe plaque psoriasis. The data showed th…
- InnoCare’s TYK2 inhibitor soficitinib meets primary endpoint in phase 2 vitiligo trialInnoCare Pharma announced that its TYK2 inhibitor soficitinib achieved the primary endpoint in a phase 2 study of non‑segmental vitiligo conducted at sites in China. The trial evaluated daily oral…